📰 Buprenorphine and Dental Damage What Patients Actually Need to Know

Purpose: In 2022, the FDA issued a warning about dental problems linked to buprenorphine medications that dissolve in the mouth. Since then, information has spread quickly—some accurate, some exaggerated, and much of it missing important context. This page explains what is actually known, what is not, and how different products compare.

Disclaimer: This page is for educational purposes only and not a substitute for professional medical or legal advice. See full disclaimer.

1. The FDA Warning

The FDA confirmed that some patients using buprenorphine medications dissolved in the mouth—such as Suboxone, Subutex, Zubsolv, and Belbuca—have experienced serious dental issues, including:

  • Tooth decay
  • Cavities
  • Tooth loss
  • Oral infections

These cases have included patients with no prior history of dental problems.

2. Not All Buprenorphine Is the Same

This is where much of the public conversation goes wrong.

Key distinction:

  • Suboxone (OUD treatment) – typically dosed in milligrams (mg)
  • Belbuca (chronic pain treatment) – dosed in micrograms (mcg)

This is not a small difference. It represents a fundamentally different level of drug exposure.

These medications are not interchangeable and are not used for the same purpose.

3. Where the Risk Appears Strongest

FDA data show that most reported dental cases are associated with opioid use disorder (OUD) products, particularly Suboxone and similar medications.

Important clarified statement:

Reported dental cases are mainly associated with OUD-based buprenorphine products, especially Suboxone and similar mouth-dissolving formulations. Separately, the current major litigation is focused on Suboxone film; there is no comparable active litigation involving Belbuca, the Butrans patch, or injectable buprenorphine.

4. What About Belbuca, Butrans, or Injections?

At this time, major litigation is not centered on Belbuca, the Butrans patch, or injectable forms of buprenorphine.

  • Suboxone film – current legal focus
  • Belbuca – some reported cases, but not the same legal pattern
  • Butrans patch – bypasses the mouth
  • Injectables (e.g., Sublocade) – bypass the mouth

Belbuca should not be considered risk-free, but it should not be treated as equivalent to Suboxone film either.

5. Why Form Matters

The primary risk factor identified is prolonged exposure in the mouth.

  • Sublingual and buccal films dissolve over time
  • This creates extended contact with teeth and gums

Important:

  • Butrans patch (transdermal) – bypasses the mouth
  • Injectables – bypass the mouth

These do not carry the same dental exposure concern.

6. Proper Dental Guidance

Some sources incorrectly state that patients should wait 30 minutes before brushing.

Correct guidance:

  • Rinse the mouth with water after the medication fully dissolves
  • Wait at least one hour before brushing

This recommendation exists because enamel may be temporarily softened, and brushing too soon can increase the risk of damage.

7. Fluoride and Prevention Claims

Fluoride may help strengthen enamel, but it is not a guaranteed solution.

The FDA does not identify fluoride as a preventive measure for buprenorphine-related dental damage.

Dental outcomes depend on multiple factors:

  • Frequency of exposure
  • Saliva production
  • Oral hygiene
  • Individual biology

8. What Is Still Unknown

The current evidence does not establish:

  • That every patient will experience dental damage
  • That all products carry equal risk
  • That a single cause explains all cases

The FDA states it cannot predict which patients will develop dental problems.

9. What Patients Should Take Away

  • There is a documented dental risk with buprenorphine products dissolved in the mouth
  • Most cases are associated with OUD products, especially Suboxone film
  • Products differ significantly in dose, purpose, and exposure

10. Bottom Line

This is not about fear—it is about informed choice.

  • Talk to your doctor
  • Talk to your dentist
  • Understand your options

Your treatment should be based on your individual needs—not a one-size-fits-all approach.

References

  1. FDA Drug Safety Communication (2022): FDA
  2. Suboxone Prescribing Information: FDA Label
  3. Belbuca Prescribing Information: Belbuca
  4. Federal MDL 3092: Court
  5. Suboxone Lawsuit Overview: Drugwatch
  • Educational purpose only: This page explains medication risks and differences in plain language.
  • Not treatment advice: Decisions should be made with licensed professionals.
  • No one-size-fits-all medicine: Individual biology and treatment context matter.

Back to top ↑